The earnings call reflected a positive sentiment with multiple strategic milestones achieved, including successful out-licensing deals and a significant reduction in operating expenses. The company also demonstrated financial stability and progress in clinical trials. However, decreased revenues and potential challenges in regulatory approval for pancreatic cancer were noted as concerns.

Company Guidance -

Q2 2025

During the BioLineRx First Quarter 2025 Financial Results Conference Call, Philip Serlin, CEO of BioLineRx, provided detailed guidance on the company's strategic focus and financial position. He highlighted the exclusive out-licensing agreement with Ayrmid Pharma Limited for APHEXDA, an FDA-approved stem cell mobilization agent, which generated $1.4 million in sales in Q1 2025, resulting in $0.3 million in royalty revenue for BioLineRx. The company's operating cash burn was significantly reduced by over 70% to less than $12 million annually, as a result of restructuring efforts, and they ended the quarter with $26.4 million in cash. They are focusing on evaluating early-stage oncology and rare disease assets to expand their pipeline, with potential funding from milestones and royalties from agreements with Ayrmid and Gloria Bio. The company also reported promising developments in ongoing trials, including two Phase 1 trials for sickle cell disease and a Phase 2b pancreatic cancer trial, with interim analysis expected in 2026.

Successful Out-Licensing of APHEXDA

BioLineRx entered into an exclusive out-licensing agreement with Ayrmid Pharma Limited for APHEXDA, which is FDA-approved for stem cell mobilization. This agreement includes substantial commercial milestones and royalties.

Significant Reduction in Operating Expenses

BioLineRx reduced its operating cash burn by over 70%, from $40 million annually to less than $12 million, following the restructuring and out-licensing agreement with Ayrmid.

Financial Stability and Strong Cash Position

The company ended the first quarter of 2025 with $26.4 million in cash, a strong financial footing, and a cash runway expected to fund operations through the second half of 2026.

Encouraging APHEXDA Sales

APHEXDA generated $1.4 million in sales in Q1 2025, resulting in $0.3 million in royalty revenues for BioLineRx after returning to growth under Ayrmid's stewardship.

Promising Developments in Pancreatic Cancer Trial

Motixafortide showed a 64% response rate in a pilot study for pancreatic cancer, with new data to be presented at ASCO 2025. This compares favorably to historical response rates.

Bioline Rx (IL:BLRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IL:BLRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.33 / -	0	―	―	―
May 27, 2025	2025 (Q1)	- / -	0	―	―	―
Mar 31, 2025	2024 (Q4)	-0.67 / 0.00	0	―	―	―
Nov 25, 2024	2024 (Q3)	-1.00 / 0.00	-6.678	―	―	―
Aug 15, 2024	2024 (Q2)	-1.67 / 0.00	-6.678	―	―	―
May 28, 2024	2024 (Q1)	-6.34 / 0.00	-3.339	―	―	―
Mar 26, 2024	2023 (Q4)	-5.01 / -4.34	-2.003	-116.67% (-2.34)	―	―
Nov 20, 2023	2023 (Q3)	-4.67 / -6.68	-3.339	-100.00% (-3.34)	―	―
Aug 30, 2023	2023 (Q2)	-3.67 / -6.68	-3.339	-100.00% (-3.34)	―	―
May 24, 2023	2023 (Q1)	-3.00 / -3.34	-3.339	0.00% (0.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IL:BLRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 27, 2025	2.20	2.00	-9.09%
Mar 31, 2025	1.90	1.90	0.00%
Nov 25, 2024	8.70	7.50	-13.79%
Aug 15, 2024	18.10	17.70	-2.21%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioLineRX Ltd. (IL:BLRX) report earnings?

BioLineRX Ltd. (IL:BLRX) is schdueled to report earning on Aug 13, 2025, Before Open (Confirmed).

What is BioLineRX Ltd. (IL:BLRX) earnings time?

BioLineRX Ltd. (IL:BLRX) earnings time is at Aug 13, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of BioLineRX Ltd. stock?

The P/E ratio of Bioline Rx is N/A.

What is IL:BLRX EPS forecast?

IL:BLRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing